• 1
  • 2
  • 3
  • 4
  • 5

About us

MBM ScienceBridge GmbH evaluates, protects and commercializes inventions of higher education institutions and research facilities. It was founded as a private company and wholly owned subsidiary of the University of Göttingen Public Law Foundation in 2004.

We see our mission in the motivation of scientists to also look at their own research results from the perspective of an economically relevant invention and to report such to the employer as an employee invention.

In the case of promising inventions, we coordinate the application for an intellectual property right with external patent lawyers who are specialised in the relevant field

We subsequently present such inventions worldwide to companies in order to identify partners who are interested in developing the invention into a product and placing the product onto the market

New animal model for Gastrointestinal Stromal Tumor

Gastrointestinal stromal tumor (GIST) is one of the most common mesenchymal tumors of the gastrointestinal tract. GISTs occur in 10-20 per one million people. Thus, GIST has been named as an orphan drug disease. Scientists at the University of Göttingen developed a new animal drug screening model for GIST, which is caused by dysfunction of the Hedgehog pathway.

Challenge

Typically, GIST formation is driven by mutations in the KIT/CD117 gene. However, not all tumors are driven by those mutations. Hence, there is a need for animal models reflecting this situation.

Our Solution

Gross appearance of tumors of KO mice. Source: Penelope Pelczar.

Scientists at the University of Göttingen developed a new animal drug screening model for GIST, which is caused by dysfunction of the Hedgehog pathway. This is the first immunological GIST mouse model with an aberrant Hedgehog signaling independent of Kit, demonstrating the importance of this particular pathway in GIST formation.

Advantages

Tumors of this novel mouse model have a GIST-like histology. Source: Walter J. Schulz-Schaeffer.

  • Novel GIST animal model caused by aberrant Hedgehog pathway independent of KIT mutations.
  • Conditional gene knock-out of a key player within Hedgehog pathway in monocytes (LysM-positive cells).
  • Severe gastrointestinal phenotype without affecting otherwise normal development.
  • Good and effective breeding.

Applications

  • Excellent drug screening model for new targets within Hedgehog signaling.
  • Efficacy testing of potential new therapeutics for GIST.

Developmental Status

  • Fully characterized new mouse model for GIST.
  • Proof of concept with Imatinib treatment.

Tumors of GIST-mice are responsive to Imatinib, which is used in the treatment of human GIST. Source: Penelope Pelczar.

Patent Status

No IPR. We are selling/licensing this mouse model.

References

Pelczar et al.: Inactivation of Patched1 in Mice Leads to Development of Gastrointestinal Stromal-Like Tumors that Express Pdgfr alpha but not Kit.  Gastroenterology, 2013, 144:134 –144.

Contact

Dr. Stefan Uhle
Patent Manager Life Science
E-Mail: suhle(at)sciencebridge.de
Tel.: +49 551 30724 154
Reference: BioC-1466-UMG

Tags: Animal models

Our Partners

   

Looking for innovation

MBM ScienceBridge GmbH supports scientists, evaluates inventions, oversees applications for intellectual property rights and out-licenses patents of universities and research institutions in Göttingen and Lower Saxony.

Our company evaluates, protects and commercializes inventions of higher education institutions and research facilities. It was founded as a private company and wholly owned subsidiary of the University of Göttingen, Public Law Foundation, in 2004.


Office of MBM ScienceBridge GmbH:
The office of the MBM ScienceBridge GmbH resides in the Laser Laboratory on the northern campus of the Georg-August-University Göttingen.

A subsidiary of

Georg-August-Universität Göttingen